AV-COVID-19 / AiVita Biomedical - LARVOL DELTA

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2 | N=0 | Withdrawn | Sponsor: Aivita Biomedical, Inc. | N=175 ➔ 0 | Not yet recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2; N=175; Not yet recruiting; Sponsor: Aivita Biomedical, Inc.; Trial completion date: Jan 2023 ➔ Jan 2024; Trial primary completion date: Jun 2022 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2; N=175; Not yet recruiting; Sponsor: Aivita Biomedical, Inc.; Trial completion date: Sep 2022 ➔ Jan 2023; Trial primary completion date: Feb 2022 ➔ Jun 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Preventive Dendritic Cell Vaccine, AV-COVID-19, in Subjects Not Actively Infected With COVID-19 (clinicaltrials.gov) - P2; N=145; Completed; Sponsor: Aivita Biomedical, Inc.

Clinical • New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2; N=175; Not yet recruiting; Sponsor: Aivita Biomedical, Inc.; Trial completion date: Jun 2022 ➔ Sep 2022; Trial primary completion date: Nov 2021 ➔ Feb 2022

Clinical • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2; N=175; Not yet recruiting; Sponsor: Aivita Biomedical, Inc.; Trial completion date: Feb 2022 ➔ Jun 2022; Initiation date: Feb 2021 ➔ Jun 2021; Trial primary completion date: Jul 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection (clinicaltrials.gov) - P1; N=27; Completed; Sponsor: Aivita Biomedical, Inc.; Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection (clinicaltrials.gov) - P1; N=27; Active, not recruiting; Sponsor: Aivita Biomedical, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Aivita Biomedical, Inc.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Dendritic Cell Vaccine to Prevent COVID-19 (clinicaltrials.gov) - P1; N=27; Recruiting; Sponsor: Indonesia-MoH

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2

Phase I-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Adults (clinicaltrials.gov) - P1/2; N=175; Not yet recruiting; Sponsor: Aivita Biomedical, Inc.; Trial completion date: Mar 2021 ➔ Feb 2022; Initiation date: Jul 2020 ➔ Feb 2021; Trial primary completion date: Dec 2020 ➔ Jul 2021

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CSF2